Stockscreener 앱 받기
14.01
5.21%
-0.77
시장 영업 전:
14.05
0.04
+0.29%
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Panic Selling: Is Tenax Therapeutics Inc forming a double bottom2026 Institutional & Low Risk High Reward Trade Ideas - baoquankhu1.vn
CEO Moves: Is Tenax Therapeutics Inc forming a double bottom2026 Market Overview & Short-Term Trading Alerts - baoquankhu1.vn
If You Invested $1,000 in Tenax Therapeutics Inc (TENX) - Stock Titan
TENX Options Volatility — NASDAQ:TENX - TradingView — Track All Markets
TENX Options Chain — NASDAQ:TENX - TradingView — Track All Markets
TENAX Therapeutics (NASDAQ: TENX) — Morgan Stanley reports 3.5%/3.4% positions - Stock Titan
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
(TENX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
TENX SEC FilingsTenax Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
TENX Should I Buy - Intellectia AI
[EFFECT] TENAX THERAPEUTICS, INC. SEC Filing - Stock Titan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Volume Summary: What are Tenax Therapeutics Incs recent SEC filings showingOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
How (TENX) Movements Inform Risk Allocation Models - Stock Traders Daily
Tenax Therapeutics may offer up to $300 million of securities - marketscreener.com
Tenax Therapeutics May Offer Up To $300 Million Of Securities - TradingView — Track All Markets
Tenax Therapeutics (NASDAQ: TENX) registers $300M shelf to sell securities - Stock Titan
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX) - Seeking Alpha
Tenax Therapeutics (TENX): Cantor Fitzgerald Initiates Coverage with Overweight Rating | TENX Stock News - GuruFocus
Top Cypherpunk Technologies (CYPH) Competitors 2026 - MarketBeat
Published on: 2026-03-17 23:42:59 - baoquankhu1.vn
Tenax stock wins bullish view at Cantor (TENX:NASDAQ) - Seeking Alpha
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating By Investing.com - Investing.com India
Cantor Fitzgerald Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX) - MarketBeat
Tenax Therapeutics (TENX) Gains Momentum with Phase 3 Trial - GuruFocus
Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX - MarketBeat
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | - gurufocus.com
Guggenheim Issues Positive Forecast for Tenax Therapeutics (NASDAQ:TENX) Stock Price - MarketBeat
What is Lifesci Capital's Forecast for TENX Q1 Earnings? - MarketBeat
What is Lifesci Capital’s Forecast for TENX Q1 Earnings? - Defense World
Trading Systems Reacting to (TENX) Volatility - Stock Traders Daily
Logos Global Management LP Acquires 615,000 Shares in Tenax Therapeutics Inc - GuruFocus
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Raised to "Strong-Buy" at Lifesci Capital - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
TENX PE Ratio & Valuation, Is TENX Overvalued - Intellectia AI
William Blair Maintains Outperform on Tenax Therapeutics (TENX) March 2026 - Meyka
Tenax Therapeutics Inc (TENX) Q4 Loss Widens, But Beats Estimates - AlphaStreet
Analysts Are Bullish on These Healthcare Stocks: Tenax Therapeutics (TENX), Esperion (ESPR) - The Globe and Mail
Christopher Giordano Discloses Investment at Tenax Therapeutics with 6.79% Stake - TradingView
Tenax Therapeutics (TENX) CEO reports 6.79% beneficial ownership stake - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
TENX: LEVEL trial enrollment completed early; global expansion and regulatory preparations advancing - TradingView
Tenax Therapeutics stock gains as trial enrollment complete By Investing.com - Investing.com Canada
Tenax Therapeutics Achieves Phase 3 LEVEL Study Patient Target and Reports 2025 Financial Results; Topline Data Expected Q3 2026 - Minichart
Tenax Therapeutics stock holds at Outperform at Leerink Partners By Investing.com - Investing.com Canada
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
2.69%
0.25%
자본화:
|
볼륨(24시간):